Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-07-07 16:08:03 ET · period of report 2026-07-02 · accession 0000875320-26-000243 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-07 16:08 | 2026-07-02 | VRTX | McKechnie Duncan | EVP, Chief Commercial Off | S - Sale | $519.00 | -1,541 | 11.0K | -12% | -$799.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-02 | S | D | 1,541 | $519.00 | 11,001 | D | — | — | (F1) Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. |